Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
ULURU Inc. · with United States Department of Defense · NCT05496296
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 300
- US sites recruiting
- 13
- Study start
- April 30, 2023
- Record last updated
- November 20, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® in patients with stage 2, stage 3 and stage 4 pressure injury wounds. Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Subjects can be enrolled in the study either as an outpatient, or while hospitalized. Half of the subjects will be randomized to standard of care treatment, and the other half will be randomized to Altrazeal®. There are a total of up to 12 study visits taking place over 12 weeks.
Being studied: Altrazeal® Transforming Powder Dressing
Conditions: Pressure Ulcers Stage II; Pressure Ulcers Stage III; Pressure Ulcer, Stage IV
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 to 85 years of age;
- Stage 2, 3, or 4 Pressure Injuries;
- Wound exudate is mild to moderate;
- No clinically active wound infection (clinical diagnosis);
- Able and willing to provide written (not proxy) informed consent;
- Clinically stable, as determined by assessment of medical history, vital signs, physical examination, and laboratory testing prior to enrollment.
Exclusion Criteria
- Known allergy or hypersensitivity to TPD or its components;
- Pressure injuries classified as unstageable, deep tissue pressure injury, or Stage 1;
- Heavily exudative wounds;
- Wound infection as defined as the presence of a least two of the following: local swelling or in duration, erythema >0.5cm around the ulcer in any direction, local tenderness or pain local warmth and purulent discharge;
- Poorly controlled diabetes with HgbA1C >12 (as documented in the last 3 months);
- Body Mass Index (BMI) >45 kg/m2;
- Venous stasis disease or lymphedema in the affected limb (if wound is located on the limb);
- Moderate to severe chronic limb ischemia Ankle Brachial Index (ABI) \<0.7 on the affected limb, if wound is located on the limb);
- Received immunosuppression or biologics in the last six weeks and/or is expected to receive either at any point during the study;
- Selected concurrent treatments (e.g., hyperbaric oxygen, topical oxygen therapy, electrical stimulation, ultrasound, cellular or acellular skin substitutes) during study period that may impact study outcomes;
- Wounds with necrosis unable to undergo prior definitive debridement;
- Fistulas;
- Active gangrene;
- Untreated HIV;
- Currently pregnant or lactating;
- Impending organ transplant;
- Vulnerable populations including prisoners, pediatrics, cognitively impaired, unconscious, and illiterate patients;
- Unwilling or unable to comply with offloading recommendations;
- If, in the opinion of the clinical investigator, a subject is a poor candidate for this study because:
- Unable to keep research appointments;
- Poorly controlled incontinence which may impact study outcomes (e.g., depending on the location of the wound);
- Participated in another investigative study within 3 months of enrollment that could interfere with study outcomes;
- Active alcohol or substance abuse (cocaine, heroin, or other substances) that may interfere with healing or subject compliance with visit schedules;
- Concurrent clinical condition(s) that could pose a health risk to patient or influence outcome of study;
- Not suitable for study participation. -
Recruiting US locations
San Diego VA
San Diego, CA 92161
Site contact: Henry York, MD · 858-552-8585 · Henry.York@va.gov
Medstar Georgetown University Hospital
Washington D.C., DC 20007
Site contact: Deanna Curbeam · 202 444 8751 · Deanna.Curbeam@medstar.net
MedStar National Rehabilitation Hospital
Washington D.C., DC 20010
Site contact: Suzanne L Groah, MD · (202) 877-1000 · Suzanne.L.Groah@medstar.net
Medstar Franklin Square Medical Center
Baltimore, MD 21237
Site contact: Paul Carroll, DPM · (443) 777-7000 · paul.j.carroll@medstar.net
Medstar Good Samaritan Hospital
Baltimore, MD 21239
Site contact: Lumanti Manandhar · (443) 444-8000 · lumanti.Manandhar@medstar.net
Rutgers New Jersey Medical School, Ambulatory Care Center-Wound Care Clinic
Newark, NJ 07103
Site contact: Mark Granick, MD · 973-972-1129 · mgranickmd@njms.rutgers.edu
Northwell Health System/Zucker School of Medicine
Lake Success, NY 11042
Site contact: Sally Kaplan, RN · 516-233-3781 · skaplan2@northwell.edu
NYU Langone Hospital-Long Island
Mineola, NY 11501
Site contact: Scott Gorenstein, MD · 516-663-8498 · Scott.gorenstein@nyulangone.org
James J. Peters VA Medical Center
The Bronx, NY 10468
Site contact: Galea Marinella, MD · 718-584-9000 · Marinella.Galea@va.gov
Westchester Medical Center, 100 Woods, Road, Taylor Care Pavillion
Valhalla, NY 10595
Site contact: Carlo Gwardschaladse, PA · 914-493-3047 · Carlo.Gwardschaladse@wmchelath.org
University of Pittsburgh Medical Center (UPMC) Presbyterian
Pittsburgh, PA 15213
Site contact: Cecilia Zamarripa, PhD, RN, CWON · 412-647-7728 · zamarripaca@upmc.edu
VA North Texas Healthcare System
Dallas, TX 75243
Site contact: David Truong, DPM · 214-857-2602 · David.Truong1@va.gov
Michael E. DeBakey Houston VAMC
Houston, TX 77030
Site contact: Aimee Garcia, MD · 512-387-1876 · Aimee.Garcia@va.gov
Study contacts (from the official record)
- Kerry Wallace · 513 702 7536 · kwallace@altrazeal.com
- Susan St. John, MSN · sstjohn@altrazeal.com
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55